Biome Grow Past Earnings Performance

Past criteria checks 0/6

Biome Grow has been growing earnings at an average annual rate of 4.3%, while the Pharmaceuticals industry saw earnings growing at 59.3% annually. Revenues have been declining at an average rate of 21.8% per year.

Key information

4.3%

Earnings growth rate

5.3%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate-21.8%
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Auditors Have Doubts About Biome Grow (CSE:BIO)

May 07
Auditors Have Doubts About Biome Grow (CSE:BIO)

Does Biome Grow (CSE:BIO) Have A Healthy Balance Sheet?

Mar 18
Does Biome Grow (CSE:BIO) Have A Healthy Balance Sheet?

Does Biome Grow (CSE:BIO) Have A Healthy Balance Sheet?

Dec 03
Does Biome Grow (CSE:BIO) Have A Healthy Balance Sheet?

Revenue & Expenses Breakdown

How Biome Grow makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:BIO Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230-210
30 Jun 230-310
31 Mar 230-710
31 Dec 220-1110
30 Sep 220-1010
30 Jun 220-1310
31 Mar 220-2110
31 Dec 210010
30 Sep 210610
30 Jun 210530
31 Mar 2101740
31 Dec 200-240
30 Sep 200-1240
30 Jun 20-2-930
31 Mar 200-940
31 Dec 190-940
30 Sep 190-1070
30 Jun 192-970
31 Mar 190-960
31 Dec 180-950
30 Sep 180-330
30 Jun 180-220
31 Mar 180-110
31 Dec 170-110

Quality Earnings: BIO is currently unprofitable.

Growing Profit Margin: BIO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BIO is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.

Accelerating Growth: Unable to compare BIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).


Return on Equity

High ROE: BIO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/04 18:34
End of Day Share Price 2024/05/07 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biome Grow Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siddharth RajeevFundamental Research Corp.